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Abstract 
Cyclopamine- and paclitaxel-containing hetero-nanoparticles generated by self-assembly show 
combined efficacy in the treatment of three different cancer cell lines. The use of ternary combination 
with the addition of a dye-squalene conjugate secured the obtainment of fluorescent nanoparticles that 
permit-ted the observation of the cellular internalization by confocal microscopy and super-resolution 
dSTORM (direct stochastic optical reconstruction microscopy).  
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Tumors are heterogeneous, composed of distinct types of cells including cancer stem cells (CSCs), 
which exhibit high clono- genic capacity and the ability to reform parental tumors upon transplantation. 
Existing anticancer therapies are in most cases palliative rather than curative, not being able to prevent 
re- lapse. One possible explanation is that current treatments target the more differentiated tumor cells 
resulting in tumor regression; they do not target CSCs, and subsequently there is a relapse of the 
disease. Indeed, resistance to therapy has been shown for several types of CSCs. Therefore, a 
combination of agents against both CSCs and bulk tumor cells may offer improved therapeutic 
benefits.[1] In this field, the use of a combination of paclitaxel, a known microtubule stabilizer, and 
cyclopamine, a natural alkaloid acting as Hedgehog signalling pathway (Hh) inhibitor, has been 
reported for the treatment of some prostate cancer cells resulting in decreased proliferation and 
increased apoptosis.[2,3]  
The use of nanotechnology can overcome some problems of drug delivery[4–10] improving the cell 
internalization of other- wise insoluble, unstable, or unavailable therapeutic com- pounds and reducing 
the dosage of those compounds and the associated side effects.[11] In this light, we recently described 
the preparation of a novel class of squalene-based releasable compounds conjugated with paclitaxel, 
podophyllotoxin, camptothecin, and epothilone A. Owing to the presence of the squalene tail and the 
disulfide-containing linker, the derivatives self-assembled in water to form nanoparticles and the drug 
was released after cell internalization[12] as a possible consequence of the presence of glutathione 
(GSH). Couvreur et al. reported the possibility to obtain self-assembled fluorescent hetero-
nanoparticles.[13] In our case, we recently described the combination of paclitaxel–squalene and 
fluoresceine–squalene conjugates to trace the delivery of the nanoassemblies and to investigate the 
internalization mechanism.[14]  
Following our interest in the synthesis and functionalization of new anticancer compounds,[15–21] we 
examine self-assembled hetero-nanoparticles that incorporate two different drugs: paclitaxel and 
cyclopamine (1a). A ternary combination obtained by further addition of a tetramethylrhodamine–
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squalene conjugate generated fluorescent nanoparticles that could be used to observe the cellular 
internalization by confocal microscopy and super-resolution dSTORM.[22]  
We first investigated the synthesis of cyclopamine–squalene conjugates incorporating a disulfide bond. 
In Scheme 1 we report a successful synthesis that relies on the protection of the amino group.[4] 
Condensation of cyclopamine N-Fmoc (1b)[23] with dicarboxylic acid monoesters 2a,b[12] in the pres- 
ence of EDC–DMAP and subsequent removal of the protecting group led to cyclopamine conjugates 
3a,b.The conjugates ob- tained were used to form nanoparticles by the solvent-dis- placement method 
which were characterized by quasi elastic light scattering (QELS) (Table 1).  
To assess the effect of the compounds 3 a and 3 b on cancer cell growth, we evaluated their biological 
effect in U251 glioblastoma cell line taking into account that their resistance is associated also with an 
increase of GSH level.[24] We found compound 3 b to be the more active (Figure S1 in the Support- 
ing Information). Our results show that the compound 3 b inhibited proliferation (Table 1) and induced 
apoptosis at comparable levels to that of cyclopamine, and this effect was indeed mediated by 
inhibition of the Hh pathway (Figure S1 in the Supporting Information). In our proposal, compound 3 a 
releases the drug as a consequence of the cleavage of the disulfide bond by glutathione (GSH), which is 
particularly present inside the cancer cells. If the release of cyclopamine is responsible for the activity, 
the unexpected result seems to suggest a better release in compound 3 b. With the aim to evaluate the 
chemical reactivity induced by the presence or the absence of the disulfide bond, we studied the 
behavior of both compounds 3a and 3b in the presence of GSH. With ESI mass spectrometry we had 
the possibility of detecting the release of cyclopamine from both of the compounds. In the absence of 
GSH we observed only the peaks of the conjugate (see the Supporting In- formation).  
Given the better activity of compound3b, we decided to use compound 3 b and compound 4[12] to 
form hetero-nanoparticles. Hetero-nanoparticles having different molar ratios of the two compounds 
were prepared; the results obtained with the most active nanosuspension (molar ratio 3 b/4 23 :1). 
Hetero-nanoparticles were characterized using QELS (Table 1) and the morphology was evaluated by 
AFM (Figure 1). Biological evaluation of hetero-nanoparticles (Table 1) showed that the activity of the 
two drugs was maintained and comparable to the activity of nanoassemblies of compounds 3 b and 4 in 
different cellular systems, that is, OVCAR5 (ovarian cancer cell) and #83 and #110 (ovarian tumor-
initiating cells).[25] The inhibition of U251 proliferation (Figure S2 in the Supporting Information) and 
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induction of apoptosis (Figure 2) showed a combined effect. It is worth noting that the IC50 value 
reported for 3b/4 NPs refers to sum of the concentrations of the two compounds assembled in the 
hetero-nanoparticles: this means that for the reported values 23/24 is due to compound 3 b and 1/24 to 
compound 4. As an example, the IC50 obtained for 3 b/4 in U251 cells corresponds to a concentration 
of compound 4 equal to 1.2 mm and to a concentration of compound 3 b equal to 26.8 mm, both lower 
than the IC50 obtained for the corresponding homo-nanoparticles.  
Next, we aimed to monitor the ability of the hetero-nanoparticles to pass through the cell membrane in 
biological media. In order to apply fluorescence microscopy, we assembled hetero-NPs that 
incorporated a squalene–tetramethylrhodamine (TAMRA) conjugate (6). TAMRA was chosen as a 
fluorescent dye because it is used in super-resolution localization microscopy techniques such as 
dSTORM (direct stochastic optical reconstruction microscopy).[26] The fluorescent squalene conjugate 
was synthesized by reaction of tetramethylrhodamine isothiocyanate (5) with compound 7[12] in the 
presence of sodium hydride (Scheme 2). The fluorescent hetero-nanoparticles were obtained by the 
solvent-displacement method by mixing compounds 3 b, 4, and 6 in a 23 :1:15 molar ratio ; we 
confirmed by QELS the formation of the nanoparticles [mean diameter : (224 2) nm, zeta potential : (+ 
43.5 3.4) mV] .  
Breast cancer MCF-7 cells were treated with the fluorescent hetero-nanoparticles for 20 min and 
imaged by multiple fluorescence microscopy methods. Three-dimensional confocal microscopy (Figure 
3) allowed the identification of the fluorescent nanoparticles in the cytoplasm of the cells, providing 
evi- dence that the nanoparticles are capable of permeating the cellular membrane. However, to provide 
an estimation of the size of the NPs, the resolution of conventional microscopy is not sufficient. We 
therefore applied super-resolution microscopy (dSTORM)[27] to quantify the diameter of the bright 
particles detected inside the cells. Figure 4 shows images of the cells re- corded after 1.5 h of 
incubation. The enlarged detail of the NP served to quantify its diameter : 156 nm. The diameter is in 
good agreement with our previous measurements by QELS [(224 2) nm] . In order to monitor the 
behavior of the internalized NPs, we performed dStorm imaging at different incubation times. In this 
way we confirmed (Table 2) a progressive in- crease in the variability of the nanoparticle diameter—as 
indicated by the increase in the coefficient of variation—which might be an indication of their tendency 
to disassemble.  
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In conclusion, we have demonstrated the possibility of forming hetero-nanoparticles containing two 
different drugs and we also established that the two drugs that do not influence each other’s activity. 
We confirmed the possibility of following the internalization mechanism by the addition of a third dye- 
based compound using super-resolution microscopy. Our approach is based on simple chemical 
functionalization of known anticancer compounds that self-assemble to form nanoparticles. In 
principle, this could improve drug biocompatibility and delivery efficacy. In this specific study the 
discussed approach yielded results that may be useful in overcoming resistance due to cancer stem 
cells. We consider that the functionalization of different known drugs with a cleavable linker and a 
proper lipophilic chain that induces self-assembly and the generation of hetero-nanoparticles could be 
exploited for personalized treatment of different types of diseases, and it may be possible to trace these 
nanoparticles in the cells by imaging.  
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